Last updated: March 11, 2026
What is the Approved Indication and Formulation?
NDC 65862-0586 corresponds to Tepmetko (tepotinib), a kinase inhibitor approved by the FDA for treatment of non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations. Tepmetko is administered orally in capsule form and is a targeted therapy designed to inhibit MET-driven tumor growth.
Product Status and Regulatory Timeline
- Approved by FDA: February 2023.
- Authorizations in other jurisdictions: Approval pending or ongoing assessments in EU, Japan, and Canada.
- Patent life: The patent protection extends until 2039, with additional orphan drug exclusivity through 2028.
Market Dynamics
Market Size Overview
The global NSCLC market reached approximately $15 billion in 2022, with targeted therapies comprising roughly 20% of this revenue. MET alterations occur in about 3-4% of NSCLC cases, representing a subset of 200,000 patients globally annually.
Competitive Landscape
- Capmatinib (Tabrecta / NRC-21-0310) by Novartis received FDA approval in May 2020 for MET exon 14 skipping NSCLC.
- Savolitinib under investigation, with some approvals in China.
- Several emerging drugs target MET alterations, but Tepmetko distinguishes itself through its selectivity and clinical trial data.
Market Entry Timing
Market penetration is expected to accelerate post-approval, with initial sales concentrated in early-adopter regions like the US and Europe. Market access depends on reimbursement policies, especially given the high cost of targeted therapies.
Pricing Trends and Projections
Current Pricing Framework
- Launch Price: Approximate wholesale acquisition cost (WAC) estimated at $15,000 per month or $180,000 annually.
- This pricing aligns with other targeted NSCLC therapies, accounting for the specificity of MET exon 14 skipping.
Price Evolution Factors
- Competition from Capmatinib: Capmatinib’s WAC approx. $14,000 per month.
- Cost-effectiveness evaluations and value-based pricing agreements will influence long-term price adjustments.
- Payer negotiations may lead to discounts, especially as real-world data accrues.
Future Price Trends (2023-2030)
| Year |
Estimated WAC per Month |
Key Influencing Factors |
| 2023 |
$15,000 |
Initial market entry, limited discounts |
| 2025 |
$13,750 - $15,000 |
Competitive pressure from other MET inhibitors; value-based contracts |
| 2030 |
$12,500 - $14,000 |
Increased competition, biosimilar emergence predicted after patent expiry |
Path to Cost Reduction
- Patent expiry in 2039 limits immediate generic entry.
- Biosimilar or alternative formulations may emerge, gradually reducing prices by 20-30% over the next decade.
- Reimbursement negotiations could further pressure price decreases.
Revenue Projections
Based on current market size, approval, and price points:
- 2023-2025: Initial sales projected at $300-400 million annually.
- 2026-2030: With increasing adoption, sales could reach $1-2 billion annually, assuming steady market penetration and expanding indications.
Assumptions:
- Steady approval and subsequent indication approvals.
- Market share reaching 20-30% of MET exon 14 NSCLC patients.
- Reimbursement policies favor use based on demonstrated clinical benefit.
Key Challenges and Opportunities
Challenges
- Competition from Capmatinib and other emerging MET inhibitors.
- High pricing may limit adoption in cost-sensitive markets.
- Need for real-world evidence to support usage and reimbursement.
Opportunities
- Expanding indications to other MET-driven tumors.
- Combination therapies with immunotherapy or chemotherapy.
- Patent protection until 2039 guarantees market exclusivity initially, supporting premium pricing.
Summary
Tepmetko’s market landscape reflects strong potential in MET exon 14 NSCLC, with an initial high price of approximately $15,000 per month. Long-term price reductions are anticipated due to competitive pressures, biosimilar entry, and value-based arrangements. Sales are projected to grow from hundreds of millions towards several billion dollars annually by 2030 if market adoption remains robust.
Key Takeaways
- Tepmetko (tepotinib) targets a specific subset of NSCLC, with limited current competition.
- Initial pricing remains high, aligned with other targeted therapies.
- Market growth depends on expanding indications, clinical data, and reimbursement strategies.
- Price reductions are likely after patent expiration and market saturation.
- Revenue potential hinges on prescription uptake and competition management.
FAQs
Q1: Will Tepmetko’s price decrease significantly after patent expiry?
A: Yes, biosimilar or generic entry post-2039 will likely lower prices by 20-30%.
Q2: How does Tepmetko compare price-wise to Capmatinib?
A: Both drugs have similar WAC prices, generally around $14,000-$15,000 per month.
Q3: What factors could accelerate Tepmetko’s market adoption?
A: Demonstration of superior efficacy, positive real-world data, and favorable reimbursement policies.
Q4: Are there indications for Tepmetko beyond NSCLC?
A: Currently, primary indication is MET exon 14 skipping NSCLC; expansion depends on ongoing trials.
Q5: How will competition influence Tepmetko’s pricing strategy?
A: Increased competition may drive prices downward unless differentiated by superior efficacy or safety.
References
[1] American Cancer Society. (2023). Non-Small Cell Lung Cancer Facts & Figures.
[2] IQVIA. (2022). Global Oncology Market Report.
[3] U.S. Food and Drug Administration. (2023). Tepmetko (tepotinib) approval documentation.
[4] Evaluate Pharma. (2023). Oncology Market Forecasts.
[5] WHO. (2022). Global Cancer Statistics.
(Note: Actual prices, sales figures, and forecasts are hypothetical and inferred from comparable drugs and market conditions.)
